Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection
Yifan Wang
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The primary objective of this study is to evaluate the safety of iNeo-Vac-R01, an individualized mRNA therapeutic technology based on tumor neoantigens, for the adjuvant treatment of patients with biliary malignant tumors after radical resection.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- RECRUITING
- phase
- PHASE1, PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 20
- sponsor
- Yifan Wang
- conditions
- Biliary Malignant Tumors
- interventions
- BIOLOGICAL: iNeo-Vac-R01
- start date
- 2025-09-11
- start date type
- ACTUAL
- primary completion date
- 2027-09-30
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07368803
- Published
- Jan 27, 2026
- Updated
- Feb 3, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07368803
- Categories
- Biliary Malignant Tumors
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials